Skip to main content

04-01-2021 | Liraglutide (obesity) | News


EMA approves liraglutide for teenagers with obesity

Author: Eleanor McDermid


medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended approval of liraglutide 3.0 mg to treat obesity in children aged 12 years or older.

The lower 1.8 mg/day dose of the glucagon-like peptide 1 receptor agonist is already available for adolescents with type 2 diabetes. The higher dose, used to combat obesity in adults, is now recommended for approval in this younger age group based on the results of a trial published in January 2020, which showed significant weight reductions with liraglutide 3.0 mg/day versus placebo, in line with the established effect in adults.

To qualify for treatment, adolescents must have a BMI for their age and sex that corresponds to 30 kg/m2 or more for adults, and must weigh more than 60 kg. Treatment should be re-evaluated after 12 weeks if the teen has not reduced their BMI or BMI z score by at least 4%.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2021 Springer Healthcare part of the Springer Nature Group


Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video